Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

RegulatoryapprovedPositive

AI Analysis

Summary

Porton Advanced Solutions has obtained a Drug Manufacturing License (Class C) from China's NMPA, enabling expansion of its CDMO services to include commercialization-stage operations.

Outcome Details

Drug Manufacturing License (Class C) granted by NMPA

Importance:5/10

Sentiment:

0.70

CDMOmanufacturingregulatory approvalChinacommercialization

Related Companies

$NHC

Read the original article

Published by PR Newswire Clinical Trials on August 5, 2026 11:31 AM

Read Original